Previous close | 21.40 |
Open | 21.35 |
Bid | 21.26 x 200 |
Ask | 21.37 x 200 |
Day's range | 21.17 - 21.67 |
52-week range | 13.82 - 24.21 |
Volume | |
Avg. volume | 645,888 |
Market cap | 1.924B |
Beta (5Y monthly) | 1.96 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.17 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 24.36 |
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.